Give classification of,diuretics according to potency and site of action and mechanism of action and therapeutic uses and adverse effects of thiazides and mechanism of action and, therapeutic uses of furosemide

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive information from Katzung's Basic and Clinical Pharmacology and Goodman & Gilman's to compose a complete, authoritative answer. Let me compile everything.

Diuretics: Complete Overview

1. Classification of Diuretics

A. By Potency (Efficacy - % NaCl Excretion)

Potency Class	Agents	Max NaCl Excreted
High efficacy (High ceiling)	Loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid)	15-25% of filtered NaCl
Moderate efficacy	Thiazides (HCTZ, chlorthalidone, indapamide, metolazone)	5-10%
Low efficacy	Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene); Carbonic anhydrase inhibitors (acetazolamide)	<5%
Variable (osmotic)	Osmotic diuretics (mannitol, glycerin)	Variable

Loop diuretics are the most efficacious because the thick ascending limb (TAL) of Henle's loop has the largest NaCl absorptive capacity of any nephron segment, and their action is not limited by development of acidosis. - Katzung's Basic and Clinical Pharmacology, 16th Ed.

B. By Site of Action and Drug Class

Class	Site of Action	Drugs
Carbonic anhydrase inhibitors	Proximal convoluted tubule (PCT)	Acetazolamide, dorzolamide
Osmotic diuretics	PCT + descending loop of Henle (primary: TAL)	Mannitol, glycerin, isosorbide, urea
Loop diuretics	Thick ascending limb (TAL) of loop of Henle	Furosemide, bumetanide, torsemide, ethacrynic acid
Thiazide diuretics	Distal convoluted tubule (DCT)	Hydrochlorothiazide, chlorothiazide, chlorthalidone, indapamide, metolazone, bendroflumethiazide
Potassium-sparing diuretics	Late DCT and collecting duct (CD)	Amiloride, triamterene (ENaC inhibitors); Spironolactone, eplerenone, finerenone (aldosterone antagonists)

2. Thiazide Diuretics

A. Mechanism of Action

Thiazides inhibit the Na+/Cl- cotransporter (NCC) on the luminal side of epithelial cells in the distal convoluted tubule. By blocking this transporter, they prevent NaCl reabsorption. Unlike loop diuretics acting on the TAL, this site reabsorbs only 5-10% of the filtered sodium, explaining their moderate potency.

In the acute phase, blood pressure falls due to decreased plasma volume, reduced cardiac output, and reduced renal blood flow.
With long-term use, plasma volume normalizes but blood pressure remains reduced because of a direct decrease in peripheral vascular resistance that develops after a few weeks.
Thiazides also increase Ca2+ reabsorption in the DCT (opposite of loop diuretics), which reduces urinary calcium loss.

Katzung's Basic and Clinical Pharmacology, 16th Ed.; Lippincott Illustrated Reviews: Pharmacology

B. Therapeutic Uses of Thiazides

Indication	Notes
Hypertension	First-line therapy; used alone or in combination with ACE inhibitors, ARBs, beta-blockers, potassium-sparing diuretics
Edema	Mild-moderate edema (heart failure, hepatic cirrhosis, nephrotic syndrome) - NOT effective if GFR < 30 mL/min/m², except metolazone
Nephrogenic diabetes insipidus	Paradoxically reduce polyuria by contracting plasma volume, reducing GFR, and increasing proximal tubular reabsorption
Hypercalciuria / calcium nephrolithiasis	Reduce urinary Ca2+ excretion; prevent calcium stone recurrence
Osteoporosis	Adjunct; reduction in calciuria may improve bone mineral density
Heart failure (mild)	In combination with loop diuretics for diuretic resistance (metolazone is particularly useful synergistically)

C. Adverse Effects of Thiazides

Metabolic Effects

1. Hypokalemia - Most common. Caused by increased Na+ delivery to the collecting duct, stimulating K+ and H+ secretion. Can precipitate cardiac arrhythmias and digitalis toxicity. Requires monitoring and K+ supplementation or combination with K+-sparing diuretics.

2. Hyponatremia - An important and potentially serious adverse effect. Caused by a combination of hypovolemia-induced ADH elevation, reduced renal diluting capacity, and increased thirst. Elderly women are most vulnerable. May cause acute angle-closure glaucoma from hypoosmolarity.

3. Hyperuricemia / Gout - Thiazides are the diuretics most associated with gout. Competition between thiazide secretion and uric acid secretion via the organic acid transporter in the proximal tubule reduces uric acid excretion, raising serum urate levels.

4. Hyperglycemia - Mild; caused by impaired insulin secretion (hypokalemia inhibits pancreatic beta cells) and possibly by reduced peripheral glucose uptake. Can worsen pre-existing diabetes or precipitate new-onset diabetes with prolonged use.

5. Hyperlipidemia - Thiazides cause a 5-15% increase in total serum cholesterol and LDL. Levels may return toward baseline with prolonged use.

6. Hypomagnesemia - More common with thiazides than loop diuretics; usually seen after > 1 year of use.

7. Hypercalcemia (mild) - Reduced urinary calcium loss; calcium levels may rise, particularly in patients with underlying hyperparathyroidism.

8. Metabolic alkalosis - Secondary to hypokalemia and volume contraction.

Other Adverse Effects

9. Allergic reactions - Thiazides are sulfonamide derivatives; cross-reactivity with other sulfonamides. Photosensitivity, generalized dermatitis, rarely hemolytic anemia, thrombocytopenia, and acute necrotizing pancreatitis.

10. Skin cancer risk - Thiazides may increase incidence of non-melanoma skin cancers (squamous cell > basal cell). A meta-analysis of >10 million people found ORs of 1.35 for squamous cell, 1.05 for basal cell, and 1.10 for melanoma. Risk appears dose-dependent.

11. Sexual dysfunction - Impotence reported; probably related to volume depletion.

12. Weakness, fatigue, paresthesias - Occur at higher doses.

Contraindication: Avoid in hepatic cirrhosis, borderline renal failure (GFR < 30 - except metolazone), sulfonamide allergy, pregnancy (first-trimester concerns).

3. Furosemide (Loop Diuretics)

A. Mechanism of Action

Furosemide inhibits the NKCC2 (Na+/K+/2Cl- cotransporter) on the luminal membrane of cells in the thick ascending limb of the loop of Henle. This is a kidney-specific cotransporter (distinct from NKCC1 in the inner ear and other tissues).

Consequences of NKCC2 inhibition:

Inhibits NaCl reabsorption in the TAL - up to 15% of the filtered load, producing powerful diuresis.
Abolishes the lumen-positive transepithelial potential that normally drives passive reabsorption of Mg2+ and Ca2+ - resulting in increased excretion of both cations (hypercalciuria, hypomagnesemia).
Reduces medullary tonicity by preventing the buildup of the corticomedullary gradient - impairs urinary concentrating and diluting ability.
Increases Na+ delivery to the distal nephron - stimulates K+ and H+ secretion by the collecting duct (via aldosterone stimulation and ENaC), causing hypokalemic metabolic alkalosis.
Induces COX-2 expression - promotes PGE2 synthesis, which inhibits salt transport in the TAL and mediates renal vasodilation (increases renal blood flow). NSAIDs can blunt this effect.
Venodilatory effect - furosemide and ethacrynic acid reduce pulmonary congestion and left ventricular filling pressure via prostaglandin-mediated effects on peripheral vascular tone before measurable diuresis begins, which is clinically important in acute pulmonary edema.

Katzung's Basic and Clinical Pharmacology, 16th Ed.; National Kidney Foundation Primer on Kidney Diseases, 8th Ed.

B. Therapeutic Uses of Furosemide

Indication	Notes
Acute pulmonary edema	IV furosemide causes immediate venodilation (within minutes), reducing preload before diuresis begins; drug of choice for emergency management
Congestive heart failure (chronic)	Most widely used diuretic in heart failure; reduces ventricular preload and symptoms of congestion; improves cardiac efficiency
Hypertension with renal insufficiency	Effective even with reduced GFR (unlike thiazides, which lose effectiveness when GFR < 30); often required in CKD
Nephrotic syndrome edema	High doses often needed due to reduced protein binding (less drug secreted into tubular lumen)
Cirrhotic ascites	Combined with spironolactone
Hypercalcemia	With IV saline infusion - enhances urinary calcium excretion (calciuresis); used in emergency management of hypercalcemia of malignancy
Hyperkalemia	Increases urinary K+ excretion; adjunct in management of mild hyperkalemia or as part of acute hyperkalemia protocol
Acute renal failure	Increases urine flow and K+ excretion but does NOT prevent or shorten the course of acute tubular necrosis
Anion overdose	Bromide, fluoride, iodide - all reabsorbed in the TAL; furosemide promotes their excretion
Edema of any cause	Hepatic, renal, cardiac

Summary Comparison: Furosemide vs Thiazides

Feature	Furosemide (Loop)	Thiazides
Site	Thick ascending limb	DCT
Potency	High (up to 25% Na excretion)	Moderate (5-10%)
Effective in renal failure (GFR < 30)	Yes	No (except metolazone)
Ca2+ effect	Increases excretion (hypocalcemia risk)	Decreases excretion (hypercalcemia risk)
Mg2+ effect	Increases excretion	Increases excretion (more with thiazides)
Main adverse effect	Hypokalemia, ototoxicity	Hypokalemia, hyperglycemia, hyperuricemia
Use in hypertension	Rarely alone; for resistant/edematous HTN	First-line
Onset (IV)	Immediate venodilation, diuresis in 30 min	N/A (oral)

Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed. (Chapter 15); Lippincott Illustrated Reviews: Pharmacology; Goodman & Gilman's Pharmacological Basis of Therapeutics (Chapters 29, 33); National Kidney Foundation Primer on Kidney Diseases, 8th Ed.

From here u will only Answer my questions only

Understood. I will only answer your questions. Go ahead and ask!

And give me answers for 5-6 marks for bpharm gtu 5th sem pharmacology 2

Noted. From now on, all my answers will be:

Exam-ready for B.Pharm GTU 5th Semester Pharmacology 2
5-6 marks level — structured, point-wise, with headings, suitable for GTU answer sheets
Concise but complete — covering exactly what a GTU examiner expects
No extra fluff — straight to the point

Go ahead and ask your question!

Now give the answer of above diuretic question

Here is the GTU B.Pharm 5th Sem, Pharmacology 2 exam-ready answer:

Diuretics

Definition

Diuretics are drugs that increase urine output by increasing renal excretion of water and electrolytes (mainly Na+ and Cl-).

Classification of Diuretics

A. According to Potency

Class	Drugs	% Na+ Excreted
High efficacy	Loop diuretics (Furosemide, Bumetanide, Ethacrynic acid)	15-25%
Moderate efficacy	Thiazides (Hydrochlorothiazide, Chlorthalidone)	5-10%
Low efficacy	K+-sparing (Spironolactone, Amiloride, Triamterene)	<5%

B. According to Site of Action

Site of Action	Class	Drugs
Proximal convoluted tubule (PCT)	Carbonic anhydrase inhibitors	Acetazolamide
PCT + Loop of Henle	Osmotic diuretics	Mannitol
Thick ascending limb (TAL)	Loop diuretics	Furosemide, Bumetanide, Torsemide, Ethacrynic acid
Distal convoluted tubule (DCT)	Thiazides	Hydrochlorothiazide (HCTZ), Chlorthalidone, Indapamide
Late DCT + Collecting duct	K+-sparing diuretics	Spironolactone, Eplerenone, Amiloride, Triamterene

Thiazide Diuretics

Mechanism of Action

Thiazides inhibit Na+/Cl- cotransporter (NCC) on the luminal membrane of the distal convoluted tubule (DCT)
This blocks NaCl reabsorption
Acutely: Reduce plasma volume → decrease cardiac output → decrease BP
Chronically: Plasma volume normalizes but BP remains low due to decrease in peripheral vascular resistance
They also reduce Ca2+ excretion (increase Ca2+ reabsorption in DCT) — opposite of loop diuretics

Therapeutic Uses

Hypertension — First-line drug; used alone or in combination
Edema — Mild to moderate edema of cardiac, hepatic, or renal origin
Nephrogenic Diabetes Insipidus — Paradoxically reduce urine volume
Hypercalciuria / Calcium kidney stones — Reduce urinary calcium excretion, prevent recurrence
Osteoporosis — Adjunct therapy
Heart failure — Mild cases; combined with loop diuretics for diuretic resistance (metolazone)

Adverse Effects of Thiazides

Adverse Effect	Mechanism/Note
Hypokalemia	Increased Na+ to collecting duct → K+ secretion; most common ADR
Hyperuricemia / Gout	Compete with uric acid secretion in proximal tubule
Hyperglycemia	Hypokalemia inhibits insulin secretion; worsens diabetes
Hyperlipidemia	Increase serum cholesterol and LDL by 5-15%
Hyponatremia	ADH elevation + reduced diluting capacity; especially in elderly women
Hypomagnesemia	Increased Mg2+ excretion; seen after long-term use
Hypercalcemia (mild)	Reduced Ca2+ excretion
Metabolic alkalosis	Due to K+ depletion and volume contraction
Allergic reactions	Sulfonamide derivative — rash, photosensitivity, rare hemolytic anemia
Sexual dysfunction	Impotence; related to volume depletion
Skin cancer risk	Increased risk of squamous and basal cell carcinoma (dose-dependent)

Furosemide (Loop Diuretic)

Mechanism of Action

Furosemide inhibits NKCC2 (Na+/K+/2Cl- cotransporter) on the luminal membrane of the thick ascending limb (TAL) of the loop of Henle
This is the most powerful diuretic site in the nephron

Key effects of this blockade:

Inhibits NaCl reabsorption (15-25% of filtered Na+) → powerful diuresis
Abolishes lumen-positive potential → increased Ca2+ and Mg2+ excretion
Destroys the corticomedullary osmotic gradient → impairs urine concentrating ability
Increases Na+ to collecting duct → K+ and H+ secretion → hypokalemia + metabolic alkalosis
Stimulates PGE2 synthesis (via COX-2) → renal vasodilation; also causes venodilation reducing preload before diuresis begins (important in pulmonary edema)

Therapeutic Uses of Furosemide

Use	Note
Acute pulmonary edema	Drug of choice; IV causes immediate venodilation even before diuresis
Congestive heart failure	Reduces preload, venous congestion, and edema
Hypertension with renal failure	Effective even when GFR < 30 mL/min (unlike thiazides)
Nephrotic syndrome edema	High doses required
Cirrhotic ascites	Combined with spironolactone
Hypercalcemia	With IV saline — enhances urinary Ca2+ excretion (emergency use)
Hyperkalemia	Increases urinary K+ excretion
Acute renal failure	Increases urine flow; does NOT prevent AKI
Forced diuresis in poisoning	Anion overdose (bromide, fluoride, iodide)

Quick Comparison Table (for exam)

Feature	Thiazides	Furosemide (Loop)
Site	DCT	TAL of loop of Henle
Potency	Moderate	High (most potent)
Ca2+ excretion	Decreased	Increased
Effective in renal failure	No (GFR < 30)	Yes
Use in HTN	First-line	Not preferred
Unique ADR	Hyperglycemia, hyperlipidemia	Ototoxicity
Mechanism	Block NCC	Block NKCC2

This answer covers all parts of the question at the 5-6 marks GTU exam level.

What are autocoid? Write a short note on H1 receptor antagonist with adverse effect and therapeutic use of it.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the content needed. Here is the complete GTU-level answer:

Autacoids and H1 Receptor Antagonists

What are Autacoids?

The word "autacoid" comes from Greek: autos (self) + akos (remedy/medicinal agent)
Autacoids are endogenous, locally acting substances that are produced by tissues on which they act — hence they function as local hormones
They differ from circulating hormones in that they are produced by many tissues (not in specific endocrine glands) and act locally in small amounts
They are released in response to stimuli such as injury, allergy, inflammation, or stress

Examples of Autacoids

Group	Examples
Biogenic amines	Histamine, Serotonin (5-HT)
Lipid-derived autacoids	Prostaglandins, Thromboxanes, Leukotrienes, PAF
Peptide autacoids	Bradykinin, Angiotensin, Substance P
Others	Nitric oxide (NO), Adenosine

Short Note on H1 Receptor Antagonists (Antihistamines)

Definition

H1 receptor antagonists (antihistamines) are drugs that competitively block H1 receptors and prevent the actions of histamine at those receptors.

Classification

First Generation (Sedating):

Diphenhydramine, Chlorpheniramine, Promethazine, Hydroxyzine, Dimenhydrinate, Meclizine, Cyproheptadine

Second Generation (Non-sedating / Peripheral selective):

Cetirizine, Levocetirizine, Loratadine, Desloratadine, Fexofenadine, Azelastine, Olopatadine

Mechanism of Action

H1 blockers do NOT prevent formation or release of histamine
They competitively block H1 receptors on target tissues, preventing histamine-receptor interaction
They are much more effective in preventing symptoms than reversing them once they have occurred
First-generation agents also block muscarinic cholinergic, alpha-adrenergic, and serotonin receptors - explaining many of their additional effects
Second-generation agents are made more polar (e.g., carboxyl groups added), so they do NOT cross the blood-brain barrier and are specific for peripheral H1 receptors
Some agents (e.g., azelastine, ketotifen) also have mast cell-stabilizing effects

Therapeutic Uses of H1 Antagonists

Indication	Drugs Used	Note
Allergic rhinitis	Cetirizine, Fexofenadine, Loratadine, Chlorpheniramine	First-line; controls rhinorrhea, sneezing, itching (NOT nasal congestion)
Urticaria (hives) and pruritus	Any antihistamine	Histamine is the principal mediator
Allergic conjunctivitis	Azelastine, Olopatadine, Ketotifen (eye drops)	Topical ophthalmic use
Anaphylaxis (adjunct)	Diphenhydramine	Adjunct only; epinephrine is drug of choice
Motion sickness	Diphenhydramine, Dimenhydrinate, Meclizine, Promethazine	Must be given BEFORE travel; blocks H1 and M1 receptors in vestibular pathway
Nausea and vomiting / Vertigo	Promethazine, Meclizine	Useful for vertigo in vestibular disorders
Insomnia	Diphenhydramine, Doxylamine	Used due to sedative property; not drugs of choice
Common cold (symptomatic)	Chlorpheniramine	Reduces rhinorrhea
Appetite stimulation	Cyproheptadine	Also a serotonin antagonist
Serotonin syndrome	Cyproheptadine	Adjunct management

Note: H1 blockers are NOT useful in bronchial asthma because histamine is only one of many mediators causing bronchoconstriction.

Adverse Effects of H1 Antagonists

A. First-Generation (Sedating) Adverse Effects

Adverse Effect	Mechanism	Note
Sedation	Block CNS H1 receptors	Most common ADR; fatigue, dizziness, lack of coordination
Anticholinergic effects	Block muscarinic receptors	Dry mouth, dry nose, blurred vision, urinary retention, constipation
Paradoxical CNS excitation	Especially in children	Diphenhydramine may cause hyperactivity in young children
GI disturbances	Direct effect	Nausea, epigastric distress
Postural hypotension	Alpha-adrenergic blockade	More with promethazine
Tachycardia	Anticholinergic effect
Drug interactions	Potentiate CNS depressants	Alcohol, benzodiazepines, opioids; dangerous with MAO inhibitors

B. Second-Generation Adverse Effects

Headache - most common
Minimal sedation (cetirizine and levocetirizine can cause mild sedation)
Contact dermatitis with topical diphenhydramine

Key Differences: 1st vs 2nd Generation

Feature	1st Generation	2nd Generation
CNS penetration	Yes (lipophilic)	No (polar)
Sedation	High	Minimal
Anticholinergic effects	Yes	No
Dosing frequency	4-6 hours	Once daily (12-24 hrs)
Examples	Diphenhydramine, Promethazine	Cetirizine, Fexofenadine, Loratadine

Source: Lippincott Illustrated Reviews: Pharmacology, Chapter 39

Write a note on anti Rheumatoid drugs.

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the content needed. Here is the complete GTU-level answer:

Anti-Rheumatoid Drugs (DMARDs)

B.Pharm GTU 5th Sem | Pharmacology 2 | 5-6 Marks

Definition

Anti-rheumatoid drugs are agents used in the treatment of Rheumatoid Arthritis (RA) - a chronic autoimmune inflammatory disorder causing joint destruction, synovial inflammation, and disability.

Classification of Anti-Rheumatoid Drugs

Anti-Rheumatoid Drugs
├── 1. NSAIDs (Symptomatic relief only)
│       - Ibuprofen, Naproxen, Diclofenac
├── 2. Glucocorticoids (Bridge therapy)
│       - Prednisolone, Methylprednisolone
├── 3. DMARDs (Disease-Modifying Antirheumatic Drugs)
│   ├── A. Conventional (Traditional) DMARDs
│   │       - Methotrexate, Hydroxychloroquine,
│   │         Sulfasalazine, Leflunomide
│   ├── B. Biologic DMARDs
│   │   ├── TNF-α Inhibitors: Adalimumab, Etanercept,
│   │   │     Infliximab, Golimumab, Certolizumab
│   │   ├── IL-6 Antagonists: Tocilizumab, Sarilumab
│   │   ├── IL-1 Antagonist: Anakinra
│   │   ├── B-cell depleter: Rituximab (anti-CD20)
│   │   └── T-cell costimulation blocker: Abatacept
│   └── C. Targeted Synthetic DMARDs (JAK inhibitors)
│           - Baricitinib, Tofacitinib, Upadacitinib

Key principle: DMARDs halt the disease process, slow joint destruction, and modify the disabling potential of RA. They require 2 to 6 months to show maximal effect.

A. Conventional (Traditional) DMARDs

1. Methotrexate (MTX) - Drug of Choice / First-line DMARD

Feature	Details
Mechanism	Folic acid antagonist; inhibits cytokine production and purine nucleotide biosynthesis → immunosuppressive + anti-inflammatory
Dose	Once weekly (low dose - much lower than in cancer)
Onset	3-6 weeks
Adverse effects	Mucosal ulcers, nausea, cytopenias (leukopenia), hepatic cirrhosis (long term), acute pneumonitis
Supplementation	Folic acid co-administration reduces GI and hepatic side effects
Contraindication	Pregnancy, severe hepatic disease, renal impairment
Monitoring	CBC, LFT (AST/ALT) every 8-12 weeks

2. Hydroxychloroquine (HCQ)

Feature	Details
Mechanism	Unknown in autoimmune disease; immunomodulatory
Use	Early, mild RA; often combined with MTX (triple therapy with sulfasalazine)
Onset	6 weeks to 6 months
Advantages	Least toxicity among DMARDs; lowers cholesterol; reduces diabetes risk
Adverse effects	Ocular toxicity (irreversible retinal damage - most important), corneal deposits, CNS disturbances, skin discoloration
Monitoring	Yearly ophthalmology exam after 5 years of therapy

3. Leflunomide

Feature	Details
Mechanism	Inhibits dihydroorotate dehydrogenase (DHODH) → blocks pyrimidine synthesis → arrests autoimmune lymphocytes
Use	Monotherapy if MTX intolerance or in combination with MTX
Adverse effects	Diarrhea, nausea, headache, alopecia, skin rash, hepatotoxicity, hypokalemia
Contraindication	Pregnancy (long half-life; cholestyramine washout needed before conception)
Monitoring	CBC, LFTs, electrolytes

4. Sulfasalazine

Feature	Details
Mechanism	Not fully understood in RA
Dose	1-3 g/day
Onset	1-3 months
Adverse effects	Nausea, vomiting, anorexia, leukopenia
Use	Often used as part of triple therapy (MTX + HCQ + Sulfasalazine)
Monitoring	CBC every 1 month initially, then every 6 months

B. Glucocorticoids

Examples: Prednisolone, Methylprednisolone
Used as "bridge therapy" - provide rapid symptomatic relief until DMARDs take effect
Should be used at lowest dose for shortest duration to avoid long-term adverse effects
Adverse effects: Osteoporosis, hyperglycemia, hypertension, Cushing's syndrome, immunosuppression
Always give osteoporosis prophylaxis (bisphosphonates) with long-term glucocorticoid use

C. Biologic DMARDs

Used when there is inadequate response to conventional DMARDs (especially methotrexate).

TNF-α Inhibitors (Most widely used biologics)

Drug	Type
Adalimumab	Monoclonal antibody
Etanercept	TNF receptor fusion protein
Infliximab	Chimeric monoclonal antibody
Golimumab	Monoclonal antibody
Certolizumab pegol	PEGylated antibody fragment

Mechanism: Block TNF-α, a proinflammatory cytokine that stimulates synovial cell proliferation, cartilage degradation, and bone resorption.

Adverse effects of Biologics:

Serious infections (TB reactivation, fungal infections, sepsis) - most important
Hepatitis B reactivation
Increased risk of lymphoma and other cancers
Worsening of heart failure
Live vaccines must be avoided

Other Biologics

Drug	Target	Use
Tocilizumab, Sarilumab	IL-6 receptor	RA not responding to TNF inhibitors
Anakinra	IL-1 receptor	Rarely used in RA
Rituximab	Anti-CD20 (B-cell depletion)	RA not responding to TNF inhibitors
Abatacept	T-cell costimulation (CD80/CD86 blocker)	RA not responding to TNF inhibitors

D. Targeted Synthetic DMARDs (JAK Inhibitors)

Examples: Tofacitinib, Baricitinib, Upadacitinib
Mechanism: Inhibit Janus Kinase (JAK) enzymes → block intracellular cytokine signaling
Oral agents; used when biologic DMARDs fail or are not tolerated
Adverse effects: Infections, thrombosis, hyperlipidemia

Treatment Strategy Summary

Step 1: NSAID + Glucocorticoid (bridge) + Start Methotrexate
         ↓  (if inadequate response at 3-6 months)
Step 2: Add Hydroxychloroquine ± Sulfasalazine (Triple therapy)
         OR Add biologic DMARD (TNF inhibitor preferred)
         ↓  (if still inadequate)
Step 3: Switch biologic / Add JAK inhibitor

Quick Recap Table

Drug	Mechanism	Key ADR	Monitoring
Methotrexate	Folate antagonist	Hepatotoxicity, pneumonitis	CBC, LFT
Hydroxychloroquine	Unknown	Retinal toxicity	Yearly eye exam
Leflunomide	Inhibits DHODH	Hepatotoxicity, teratogenic	CBC, LFT
Sulfasalazine	Unknown	Leukopenia, GI upset	CBC
TNF-α inhibitors	Block TNF-α	TB reactivation, infections	TB screening
Rituximab	Anti-CD20	Infusion reactions, infections	CBC

Sources: Lippincott Illustrated Reviews: Pharmacology, Chapter 40; Goldman-Cecil Medicine, Chapter 243

Mechanism of action, therapeutic uses and adverse effects of prednisolone.

Finding Sources

Reading File

I now have comprehensive data from Katzung's Pharmacology. Here is the complete GTU-ready answer:

Prednisolone (Glucocorticoid)

B.Pharm GTU 5th Sem | Pharmacology 2 | 5-6 Marks

Introduction

Prednisolone is a synthetic glucocorticoid (corticosteroid) derived from hydrocortisone (cortisol)
It has 5x more anti-inflammatory potency than hydrocortisone
Equivalent dose: 5 mg prednisolone = 20 mg hydrocortisone
Available as: oral, injectable, ophthalmic forms

Mechanism of Action

Prednisolone acts through intracellular glucocorticoid receptors (GR) - a genomic mechanism:

Step-by-Step Mechanism:

Step 1: Free prednisolone (lipophilic) diffuses across the cell membrane into the cytoplasm

Step 2: Binds to cytoplasmic glucocorticoid receptor (GR), which is normally kept inactive by heat-shock proteins (hsp90, hsp40, FKBP5)

Step 3: Binding causes conformational change → dissociation from heat-shock proteins → receptor dimerizes

Step 4: The drug-receptor complex is transported into the nucleus

Step 5: The complex binds to Glucocorticoid Response Elements (GREs) on the DNA promoter regions → modulates gene transcription

Step 6: Also binds to transcription factors AP-1 and NF-κB (which control proinflammatory cytokine genes) → suppresses them

Net Molecular Effects:

Effect	Result
Inhibits NF-κB and AP-1	Reduced synthesis of IL-1, IL-2, IL-6, TNF-α, interferons
Induces Lipocortin (Annexin-1)	Inhibits phospholipase A2 → blocks arachidonic acid release → reduces prostaglandins, leukotrienes, PAF
Inhibits COX-2 gene expression	Reduces prostaglandin synthesis
Reduces capillary permeability	Less edema and exudate
Inhibits leukocyte migration	Reduces neutrophil and macrophage recruitment to inflamed site
Suppresses lymphocyte proliferation	Immunosuppression

In short: Prednisolone blocks both the phospholipase A2 pathway (via lipocortin) and NF-κB pathway (via GR), producing potent anti-inflammatory + immunosuppressive effects.

Therapeutic Uses of Prednisolone

1. Inflammatory and Autoimmune Disorders

Condition	Use
Rheumatoid Arthritis	Bridge therapy while DMARDs take effect
Systemic Lupus Erythematosus (SLE)	Suppress disease flares
Polymyositis / Dermatomyositis	First-line treatment
Vasculitis	Reduce vascular inflammation
Inflammatory Bowel Disease	Crohn's disease, ulcerative colitis - acute flares

2. Allergic Conditions

Severe allergic reactions, anaphylaxis (adjunct to epinephrine)
Angioedema, contact dermatitis, drug reactions
Severe asthma (oral prednisolone for acute exacerbations)

3. Respiratory Diseases

Bronchial asthma - systemic use in acute severe asthma
COPD exacerbations - short-course oral therapy
Sarcoidosis

4. Skin Diseases

Pemphigus vulgaris, bullous pemphigoid
Severe eczema, psoriasis (systemic)
Lichen planus

5. Hematological Disorders

Immune Thrombocytopenic Purpura (ITP) - increases platelet count
Autoimmune Hemolytic Anemia
Acute lymphoblastic leukemia - part of chemotherapy protocols

6. Kidney Diseases

Nephrotic syndrome (minimal change disease) - first-line
Lupus nephritis, rapidly progressive glomerulonephritis

7. Neurological Disorders

Multiple sclerosis (acute relapses)
Bell's palsy
Cerebral edema (secondary to tumors)

8. Endocrine

Adrenal insufficiency (Addison's disease) - replacement therapy
Congenital adrenal hyperplasia

9. Organ Transplantation

Prevent and treat rejection (combined with other immunosuppressants)

10. Oncology

Part of chemotherapy regimens (ALL, lymphomas, multiple myeloma)

Adverse Effects of Prednisolone

A. Metabolic Effects

Adverse Effect	Mechanism
Hyperglycemia / Steroid diabetes	Increases gluconeogenesis, reduces peripheral glucose uptake, inhibits insulin secretion
Hyperlipidemia	Increased fat mobilization
Negative nitrogen balance	Protein catabolism in muscles, skin, bones
Obesity (central / cushingoid)	Fat redistribution - moon face, buffalo hump, truncal obesity

B. Musculoskeletal Effects

Adverse Effect	Note
Osteoporosis	Reduces bone formation (inhibits osteoblasts), increases bone resorption; risk of fractures - most important long-term ADR
Steroid myopathy	Muscle weakness, especially proximal limb muscles
Avascular necrosis (osteonecrosis)	Especially femoral head; with high doses
Growth retardation	In children - inhibits GH and IGF-1

C. Cardiovascular and Renal Effects

Hypertension - sodium and water retention (mineralocorticoid effect)
Hypokalemic alkalosis - K+ and H+ loss via urine
Edema - due to Na+ retention

D. Endocrine Effects

HPA axis suppression - most important with long-term use
- Abrupt withdrawal → Adrenal crisis (life-threatening)
- Must always taper gradually when stopping
Cushing's syndrome with prolonged use

E. Immunosuppression

Increased susceptibility to bacterial, viral, fungal, and TB infections
Masks signs of infection (fever, inflammation)
Reactivation of latent tuberculosis
Increased risk of opportunistic infections

F. GI Effects

Peptic ulcer disease (especially with NSAIDs)
GI bleeding, gastric perforation

G. CNS Effects

Euphoria, mood swings, psychosis ("steroid psychosis")
Insomnia, anxiety

H. Ocular Effects

Posterior subcapsular cataract (with long-term use)
Glaucoma (raised IOP)

I. Skin Effects

Skin thinning (atrophy), striae (stretch marks)
Acne, hirsutism
Easy bruising, poor wound healing

Contraindications

Contraindication	Reason
Active infections (especially TB, fungal)	Will worsen infection
Peptic ulcer disease (relative)	Risk of GI bleeding
Uncontrolled diabetes	Worsens hyperglycemia
Uncontrolled hypertension	Worsens BP
Osteoporosis	Risk of fractures
Psychosis	Can worsen psychiatric conditions
Pregnancy (high dose)	Risk of fetal effects

Important Clinical Points (for GTU exam)

Never stop prednisolone abruptly after long-term use → gradual tapering required to prevent adrenal crisis
Lowest effective dose for the shortest duration to minimize ADRs
Co-prescribe calcium + Vitamin D + bisphosphonates to prevent steroid osteoporosis
Screen for TB before starting in high-risk patients
Use proton pump inhibitor (PPI) to prevent peptic ulcer when using concomitantly with NSAIDs

Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapter 39; Lippincott Illustrated Reviews: Pharmacology, Chapter 26; Goldman-Cecil Medicine

Classify。 ...antianginal drugs and give pharmacology of nitrates。

Finding Sources

Reading File

I now have all the required content from Katzung. Here is the complete GTU-ready answer:

Antianginal Drugs

B.Pharm GTU 5th Sem | Pharmacology 2 | 5-6 Marks

Definition of Angina Pectoris

Angina pectoris is chest pain caused by myocardial ischemia - an imbalance between myocardial oxygen demand and supply. It results from accumulation of acidic metabolites in ischemic myocardium.

Types of Angina:

Stable (Effort) Angina - due to fixed atherosclerotic coronary obstruction; triggered by exercise
Variant (Prinzmetal) Angina - due to coronary artery vasospasm
Unstable Angina - acute coronary syndrome; occurs at rest; medical emergency

Classification of Antianginal Drugs

ANTIANGINAL DRUGS
│
├── 1. ORGANIC NITRATES (Nitrovasodilators)
│       • Nitroglycerin (GTN) - short-acting
│       • Isosorbide dinitrate (ISDN) - intermediate
│       • Isosorbide mononitrate (ISMN) - long-acting
│       • Amyl nitrite (inhaled)
│       • Pentaerythritol tetranitrate
│
├── 2. BETA-BLOCKERS (β-Adrenoceptor blockers)
│       • Propranolol, Metoprolol, Atenolol
│       • Bisoprolol, Carvedilol
│
├── 3. CALCIUM CHANNEL BLOCKERS (CCBs)
│       Dihydropyridines: Amlodipine, Nifedipine, Felodipine
│       Non-dihydropyridines: Verapamil, Diltiazem
│
└── 4. NEWER / MISCELLANEOUS ANTIANGINAL DRUGS
        • Ranolazine (late Na+ current blocker)
        • Ivabradine (If channel / HCN blocker)
        • Nicorandil (K+ channel opener + NO donor)
        • Trimetazidine (metabolic agent - fatty acid oxidation inhibitor)

Pharmacology of Nitrates

A. Chemistry

Organic nitric acid esters of polyalcohols
Prototype: Nitroglycerin (Glyceryl trinitrate - GTN)
All nitrates share identical mechanism; differ only in pharmacokinetics
Stored in tight glass containers (volatile); not sensitive to light

B. Mechanism of Action

Step-by-Step:

Step 1 - Bioactivation: Nitroglycerin enters vascular smooth muscle cells and is denitrated by enzymes:

Mitochondrial aldehyde dehydrogenase-2 (ALDH2) - key enzyme for NTG and pentaerythritol tetranitrate
Glutathione S-transferase - also contributes
Free nitrite ion is released → converted to Nitric Oxide (NO)

Step 2 - NO release and cGMP formation:

NO combines with the heme group of soluble guanylyl cyclase (sGC)
Activates sGC → catalyzes conversion of GTP to cGMP (second messenger)

Step 3 - Smooth muscle relaxation (via cGMP):

cGMP activates protein kinase G (PKG)
PKG phosphorylates and inactivates myosin light chain kinase (MLCK)
Without active MLCK, myosin cannot interact with actin
Result: Smooth muscle relaxation → vasodilation

Additional effects of cGMP:

Activates Ca2+-ATPase → removes Ca2+ from cell
Opens Ca2+-activated K+ channels → membrane hyperpolarization

Nitroglycerin
    ↓ (ALDH2 / Glutathione S-transferase)
Nitric Oxide (NO)
    ↓
Activates Guanylyl Cyclase
    ↓
GTP → cGMP ↑
    ↓
Inactivates MLCK
    ↓
Smooth Muscle Relaxation → VASODILATION

C. Pharmacokinetics

Feature	Details
Oral bioavailability	Very low (<10-20%) due to high first-pass metabolism in liver
Preferred route	Sublingual - avoids first-pass effect; therapeutic levels in minutes
Metabolism	Hepatic organic nitrate reductase (stepwise denitration)
Excretion	Glucuronide metabolites via kidney

Drug	Route	Onset	Duration
Nitroglycerin (sublingual)	SL tablet/spray	1-3 min	20-30 min
Nitroglycerin (transdermal patch)	Skin	30-60 min	8-12 h
Nitroglycerin (IV)	IV	Immediate	During infusion
Isosorbide dinitrate	Oral/SL	15-30 min	4-6 h
Isosorbide mononitrate	Oral	30-60 min	6-10 h

D. Organ System Effects

1. Vascular Effects (Most Important)

Vessel	Effect	Clinical Benefit
Veins (venodilation)	Increased venous capacitance → reduced venous return → decreased preload	Reduces cardiac work and O2 demand
Large coronary arteries	Dilation → increased coronary blood flow	Relieves vasospasm in variant angina
Arterioles	Mild dilation at high doses → reduced afterload	Further reduces cardiac work
Pulmonary vessels	Reduced pulmonary vascular pressure	Useful in pulmonary edema
Meningeal arteries	Dilation	Causes headache (side effect)

Primary mechanism of benefit in effort angina: Venodilation → decreased preload → decreased wall stress → decreased O2 demand

Primary mechanism in variant angina: Coronary artery dilation → relieves vasospasm

2. Cardiac Effects

Decreased heart size (reduced ventricular volume)
Indirect reflex tachycardia and increased contractility (due to baroreceptor activation from fall in BP)
Weak negative inotropic effect via NO

3. Other Smooth Muscle

Relaxes bronchi, GI tract, biliary system, genitourinary tract (mild, clinically not significant)

E. Therapeutic Uses of Nitrates

Use	Drug/Route
Acute angina attack (relief)	Sublingual NTG - drug of choice; onset in 1-3 min
Prophylaxis before exertion	SL NTG taken 5 min before activity
Chronic stable angina (prophylaxis)	Oral ISDN, ISMN; transdermal NTG patch
Variant (Prinzmetal) angina	Nitrates + calcium channel blockers (both relieve coronary spasm)
Acute LVF / Pulmonary edema	IV NTG - reduces preload rapidly
Unstable angina (ACS)	IV NTG combined with other agents
Heart failure (adjunct)	Reduces preload and pulmonary congestion

F. Adverse Effects of Nitrates

Adverse Effect	Mechanism	Note
Throbbing headache	Meningeal artery dilation	Most common; dose-dependent; may improve with continued use
Postural (orthostatic) hypotension	Venodilation → reduced venous return → reduced BP	Can cause dizziness, syncope
Reflex tachycardia	Baroreceptor activation due to BP fall	Can worsen angina; prevented by adding beta-blocker
Flushing	Cutaneous vasodilation
Methemoglobinemia	Rare; with high doses of amyl nitrite	Treated with methylene blue
Tolerance	Depletion of sulfhydryl groups; increased free radicals; neurohormonal activation	Prevented by nitrate-free interval (8-12 hours) per day

G. Nitrate Tolerance - Very Important

Develops within 24-48 hours of continuous use
Mechanism:
- Depletion of tissue sulfhydryl (cysteine-SH) groups needed for NO generation
- Increased generation of free radicals that inactivate NO
- Neurohormonal compensatory responses (salt/water retention, tachycardia)
Prevention: Provide nitrate-free period of 8-12 hours daily (e.g., remove patch at night)
Tolerance does NOT develop to sublingual NTG used as needed

H. Contraindications of Nitrates

Hypotension or hypovolemia - dangerous fall in BP
Concurrent use of PDE-5 inhibitors (sildenafil, tadalafil) - absolute contraindication - severe potentially fatal hypotension
Raised intracranial pressure - increases ICP further
Hypertrophic obstructive cardiomyopathy (HOCM) - worsens outflow tract obstruction

Quick Recap Table

Feature	Nitrates
Mechanism	NO → cGMP → ↓ MLCK → vasodilation
Primary effect	Venodilation → ↓ preload
Acute use	SL NTG (onset 1-3 min)
Prophylactic use	ISMN, ISDN oral, transdermal patch
Key ADR	Headache, hypotension, reflex tachycardia, tolerance
Tolerance prevention	Nitrate-free interval (8-12 h)
Absolute contraindication	PDE-5 inhibitors (sildenafil)

Source: Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapter 12

Classify。 ...antianginal drugs and give pharmacology of nitrates。

This question was already answered in detail just above. Here is the complete answer again for your reference:

Antianginal Drugs — Classification and Pharmacology of Nitrates

B.Pharm GTU 5th Sem | Pharmacology 2 | 5-6 Marks

Classification of Antianginal Drugs

ANTIANGINAL DRUGS
│
├── 1. ORGANIC NITRATES
│       • Nitroglycerin (GTN) — short-acting
│       • Isosorbide dinitrate (ISDN) — intermediate
│       • Isosorbide mononitrate (ISMN) — long-acting
│       • Amyl nitrite (inhaled)
│
├── 2. BETA-BLOCKERS
│       • Propranolol, Metoprolol, Atenolol, Bisoprolol
│
├── 3. CALCIUM CHANNEL BLOCKERS (CCBs)
│       • Dihydropyridines: Amlodipine, Nifedipine
│       • Non-dihydropyridines: Verapamil, Diltiazem
│
└── 4. NEWER AGENTS
        • Ranolazine (late Na+ current blocker)
        • Ivabradine (HCN / If channel blocker)
        • Nicorandil (K+ channel opener + NO donor)
        • Trimetazidine (fatty acid oxidation inhibitor)

Pharmacology of Nitrates

A. Mechanism of Action

Step-by-step:

Nitroglycerin enters vascular smooth muscle cell
        ↓
Denitrated by ALDH2 (mitochondrial enzyme)
+ Glutathione S-transferase
        ↓
Releases Nitric Oxide (NO)
        ↓
NO activates soluble Guanylyl Cyclase (sGC)
        ↓
GTP → cGMP ↑ (second messenger)
        ↓
Activates Protein Kinase G (PKG)
        ↓
Inactivates MLCK (Myosin Light Chain Kinase)
        ↓
Myosin cannot interact with Actin
        ↓
Smooth Muscle Relaxation → VASODILATION

cGMP also activates Ca2+-ATPase → expels Ca2+ from cell
Opens K+ channels → membrane hyperpolarization → further relaxation

B. Organ System Effects

Vessel	Effect	Benefit
Veins (primary)	Venodilation → ↑ venous capacitance → ↓ venous return	↓ Preload → ↓ cardiac work → ↓ O2 demand
Large coronary arteries	Dilation	Relieves vasospasm in variant angina
Arterioles (high dose)	Mild dilation	↓ Afterload
Pulmonary vessels	Dilation	Useful in acute LVF / pulmonary edema
Meningeal arteries	Dilation	Causes headache (ADR)

Key: Nitrates primarily reduce preload (by venodilation) → reduce myocardial O2 demand

C. Pharmacokinetics

Drug	Route	Onset	Duration
Nitroglycerin	Sublingual (preferred)	1-3 min	20-30 min
Nitroglycerin	Transdermal patch	30-60 min	8-12 h
Nitroglycerin	IV	Immediate	Infusion only
Isosorbide dinitrate	Oral / SL	15-30 min	4-6 h
Isosorbide mononitrate	Oral	30-60 min	6-10 h

Oral bioavailability is very low (<10-20%) due to extensive first-pass hepatic metabolism
Sublingual route avoids first-pass effect → preferred for acute attack
Excreted as glucuronide metabolites in urine

D. Therapeutic Uses

Indication	Drug / Route
Acute angina attack	Sublingual NTG — drug of choice; works in 1-3 min
Prophylaxis before exertion	SL NTG taken 5 min before activity
Chronic stable angina (prophylaxis)	Oral ISMN / ISDN, transdermal NTG patch
Variant (Prinzmetal) angina	Nitrates + CCBs (both relieve coronary spasm)
Acute LVF / Pulmonary edema	IV NTG — rapid preload reduction
Unstable angina (ACS)	IV NTG + heparin + other agents
Heart failure (adjunct)	Reduces preload, pulmonary congestion

E. Adverse Effects

Adverse Effect	Mechanism
Throbbing headache	Meningeal artery dilation — most common
Postural hypotension, dizziness, syncope	Venodilation → ↓ venous return → ↓ BP
Reflex tachycardia	Baroreceptor activation due to ↓ BP; may worsen angina
Flushing	Cutaneous vasodilation
Tolerance	Depletion of SH groups; free radical increase; neurohormonal compensation
Methemoglobinemia	Rare; with high-dose amyl nitrite

F. Nitrate Tolerance (Very Important for GTU)

Develops within 24-48 hours of continuous use
Mechanism:
- Depletion of tissue sulfhydryl (–SH) groups (needed for NO release)
- Increased free radical generation
- Compensatory neurohormonal responses (Na+/water retention, tachycardia)
Prevention: Nitrate-free interval of 8-12 hours daily
- Example: Remove transdermal patch at night
Does NOT develop with as-needed sublingual NTG use

G. Contraindications

Contraindication	Reason
PDE-5 inhibitors (Sildenafil, Tadalafil)	Absolute CI — severe fatal hypotension
Hypotension / hypovolemia	Further ↓ BP
Raised intracranial pressure	Increases ICP
HOCM	Worsens outflow obstruction

Quick Summary Table

Feature	Detail
Prototype	Nitroglycerin (GTN)
Mechanism	NO → cGMP → ↓ MLCK → vasodilation
Main effect	↓ Preload (venodilation)
Acute use	SL NTG (onset 1-3 min)
Prophylaxis	ISMN oral / transdermal patch
Key ADR	Headache, hypotension, reflex tachycardia
Tolerance	Prevented by nitrate-free interval (8-12 h)
Absolute CI	PDE-5 inhibitors

Source: Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapter 12

This is a shared conversation. Sign in to Orris to start your own chat.